Background: While point-of-care rapid HIV tests are essential to HIV prevention services in high-risk communities, these assays may not detect early HIV infection. We evaluated the cost-effectiveness of using 4th generation lab-based immunoassay (4G IA) following a negative rapid HIV test to screen for early infection. Methodology: A published mathematical model was used to estimate HIV transmissions averted and cost per quality-adjusted life years gained (QALYs) attributable to 4G IA screening following rapid testing. HIV transmissions averted due to serostatus awareness and viral load suppression were calculated for a one year period, conservatively assuming infected persons would be diagnosed one year later in the absence of 4G IA screening. Testing outcomes were derived from the STOP study, a multi-site, prospective evaluation of HIV testing methods. Participants from 12 HIV testing sites in sexually transmitted infection clinics and community-based HIV testing programs in New York City, San Francisco, and North Carolina were screened with a point-of-care rapid HIV test. Rapid negative specimens were then tested for early HIV infection with 4G IA (Architect HIV Ag/Ab Combo assay). Specimens with repeatedly reactive 4G IA results were confirmed with Multispot (HIV-1/HIV-2 Rapid Test) and discordant 4G IA/Multispot results were resolved with an HIV-1 nucleic acid amplification test. Key input values included: 80% receipt of test results, 75% uptake of antiretroviral therapy (ART), costs of $11.00 for HIV negative tests and $58.34 for HIV positive tests and treatment costs per case averted of $402,000. Testing costs were derived from a CDC micro-costing study and other model inputs from the literature. Sensitivity analyses were conducted on key variables. Results: From September 2011 to July 2013, rapid HIV testing detected infection in 963 (1.35%) of 71,616 participants. Screening of the remaining 70,653 rapid test-negative specimens with 4G IA identified an additional 127 (0.18%) infections, adding $785,700 in testing costs and $2,015,900 in total program costs (including costs for earlier ART initiation). The 4G IA testing resulted in 6.6 HIV transmissions averted, 29.2 QALYs saved, and overall cost-savings. In threshold analysis, the acute HIV positivity rate could drop to 0.13%, at which point the program is no longer cost-saving but would have a cost-effectiveness ratio of $1,900/QALY gained, and to 0.07%, and still remain below the $100,000/QALY threshold. At base case positivity rates, testing costs could increase approximately four-fold and remain below the $100,000/QALY threshold. Conclusions: Using 4G IA to screen rapid-test negative specimens for early HIV infection can be a cost-effective strategy in populations at high risk for HIV.